gms | German Medical Science

73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

29.05. - 01.06.2022, Köln

Correlation of low CD44v4 and CD44v10 gene expression levels with early tumour progression

Korrelation von niedrigen CD44v4- und CD44v10-Genexpressionsleveln mit einer frühen Tumorprogression

Meeting Abstract

  • Michael Modrok - Universitätsklinikum Jena, Klinik und Poliklinik für Neurochirurgie, Jena, Deutschland
  • Undine Tiller - Universitätsklinikum Jena, Klinik und Poliklinik für Neurochirurgie, Jena, Deutschland
  • Rosa Rühl - Universitätsklinikum Jena, Klinik und Poliklinik für Neurochirurgie, Jena, Deutschland
  • Peter Baumgarten - Universitätsklinikum Jena, Klinik und Poliklinik für Neurochirurgie, Jena, Deutschland
  • Christian A. Senft - Universitätsklinikum Jena, Klinik und Poliklinik für Neurochirurgie, Jena, Deutschland
  • Arend Koch - Charité – Universitätsmedizin Berlin, Institut für Neuropathologie, Berlin, Deutschland
  • Jan Walter - Universitätsklinikum Jena, Klinik und Poliklinik für Neurochirurgie, Jena, Deutschland; Klinikum Saarbrücken, Klinik für Neurochirurgie, Saarbrücken, Deutschland
  • presenting/speaker Diana Freitag - Universitätsklinikum Jena, Klinik und Poliklinik für Neurochirurgie, Jena, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie. Köln, 29.05.-01.06.2022. Düsseldorf: German Medical Science GMS Publishing House; 2022. DocP127

doi: 10.3205/22dgnc439, urn:nbn:de:0183-22dgnc4399

Veröffentlicht: 25. Mai 2022

© 2022 Modrok et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objective: CD44, a transmembrane glycoprotein and commonly used tumor stem cell marker, controls a variety of processes, making the identification of CSCs very difficult. This is because alternative splicing has demonstrated 10 variable forms of CD44 (CD44v1-v10) in addition to the stable form CD44s, each with distinct properties in tumor biology. The aim of this study was to investigate the expression of the different CD44 isoforms in human meningiomas and to assign possible specific cell properties by correlation with clinical data.

Methods: RNA was isolated from samples of individual meningioma patients (n=80) and analyzed by quantitative polymerase chain reaction (qPCR) for the expression of the different CD44 isoforms. Correlation of expression data with clinical data was analyzed with respect to progression-free survival (PFS) at a monitoring interval of 2 years (n=68). For this purpose, ROC analysis followed by Kaplan-Meier survival analysis was performed.

Results: All CD44 isoforms except CD44v1 and CD44v2 were detected in the majority of human meningioma samples. However, only for CD44s and CD44v3 higher relative expression levels were detected in meningiomas compared to control tissue (dura mater). Subgroup analyses between malignancy grades, however, showed that the mean relative expression levels for CD44 variants v4, v5, v7, v8, and v9 and v10 had significant differences between WHO grade I or II and control tissue.

Subsequent Kaplan-Meier analysis for PFS showed that high expression levels of v4 and v10 isoforms were associated with better outcome, particularly in male patients.

Conclusion: These analyses provide preliminary evidence for the possible involvement of the individual CD44 isoforms in the progression of human meningiomas. In addition, there is evidence that the v4 and v10 isoforms play a protective role in tumor progression.

Expression of specific CD44 isoforms appears to influence tumor growth in meningiomas, making them a potential target for therapeutic approaches in the treatment of meningiomas.